Hims & Hers stock rises due to increase in app downloads, but FDA rulings pose risks.

From Nasdaq: 2025-03-17 12:12:07

Hims & Hers Health (NYSE: HIMS) stock rises 2.2% after Morgan Stanley analyst notes a 47% increase in app downloads, primarily from women, in February. However, FDA rulings may soon prevent the company from selling certain drugs, leading to uncertain future prospects.

Analyst maintains $60 price target on Hims & Hers stock but declines to upgrade, citing high valuation. Historic “Double Down” stock recommendations from expert analysts show impressive returns, prompting current alerts for three companies. Time-sensitive opportunity to invest before potential growth.

Despite recent stock increase, uncertainties regarding FDA rulings on drug sales may impact Hims & Hers Health stock. Expert analysis suggests potential lucrative opportunities in current market conditions, urging investors to act before missing out on potential gains.



Read more at Nasdaq: Why Hims & Hers Stock Popped on Monday